Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.03. | RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 195 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip... ► Artikel lesen | |
10.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform | 113 | GlobeNewswire (Europe) | SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
28.02. | Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 283 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the... ► Artikel lesen | |
24.02. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital | 63 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
29.01. | Calidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 | 2 | GlobeNewswire (USA) | ||
28.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement | 2 | GlobeNewswire (USA) | ||
28.01. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
10.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
10.01. | Why Calidi Biotherapeutics (CLDI) Stock Is Down 30% | 1 | Benzinga.com | ||
10.01. | Calidi Biotherapeutics slumps 29%, prices $4.25M stock offering | 2 | Seeking Alpha | ||
10.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
10.01. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.01. | Calidi Biotherapeutics announces proposed public offering | 3 | Seeking Alpha | ||
08.01. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Proposed Public Offering | 2 | GlobeNewswire (USA) | ||
19.12.24 | Calidi Biotherapeutics CEO Allan Camaisa verkauft Aktien im Wert von 16.200 US-Dollar | 3 | Investing.com Deutsch | ||
12.12.24 | Calidi Biotherapeutics prices $7.5M secondary offering | 1 | Seeking Alpha | ||
12.12.24 | Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
15.11.24 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
14.11.24 | Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 30,230 | +0,15 % | Unglaubliche Prognose für Montag setzt Moderna Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
OCUGEN | 0,560 | +1,54 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
VIKING THERAPEUTICS | 26,890 | +0,49 % | Market Whales and Their Recent Bets on VKTX Options | ||
ALIGOS THERAPEUTICS | 11,100 | +6,73 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient... ► Artikel lesen | |
SAGIMET BIOSCIENCES | 3,640 | +1,68 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates | Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational... ► Artikel lesen | |
QIAGEN | 36,560 | +0,62 % | Aktie von Qiagen NV: Kurs steigt nur geringfügig (36,215 €) | Im Wertpapierhandel ist der Anteilsschein von Qiagen NV derzeit unauffällig. Die Aktie kostete zuletzt 36,22 Euro. Der Kurs der Aktie von Qiagen NV zeigt sich zur Stunde kaum verändert im Vergleich... ► Artikel lesen | |
EVOTEC | 6,320 | -2,39 % | Nicht Evotec: Steht diese Biotech-Aktie jetzt vor einer Kursexplosion? | © Foto: SpaceX auf UnsplashFür sein Alzheimer-Medikament Aducanumab wurde das US-Biotechunternehmen Biogen vor einigen Jahren noch gefeiert. Eine umstrittene Zulassung durch die US-Gesundheitsbehörde... ► Artikel lesen | |
TEMPUS AI | 50,70 | +5,54 % | Tempus AI Aktie: Anstehende Entwicklungen im Check | Die Tempus AI Aktie steht aktuell im Fokus der Anleger, nachdem mehrere Direktoren des Unternehmens in erheblichem Umfang Anteile veräußert haben. Am 17. März 2025 haben drei Vorstandsmitglieder Aktien... ► Artikel lesen | |
BEAM THERAPEUTICS | 23,260 | +1,71 % | Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).AATD... ► Artikel lesen | |
BIONTECH | 88,40 | -1,28 % | Aktien KW 11 Grüne und 500 Mrd. EUR lassen hoffen. Neue Rekorde voraus? Wenn Trump nicht… News. Hensoldt. Renk. Rheinmetall. Hypoport. Hellofresh. LAIQON. Steyr Motors. BioNTech. Puma. Mutares. MuM. Aumann. Bechtle. Hella. JDC Group. Barrick Gold ... | Aktien Wochenrückblick - sah diese Woche nach dem Beginn eines Bärenmarktes aus. Dann kam der Freitag, Grüne machen beim 500 Mrd. EUR Paket mit und auf einmal platzt der Knoten. DAX springt aus dem... ► Artikel lesen | |
TRANSCODE THERAPEUTICS | 1,170 | +51,95 % | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
BB BIOTECH | 33,400 | -8,12 % | Dividendenbekanntmachungen (21.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECON GROUP INC CA00762V1094 0,19 CAD 0,1221 EUR ALBANY INTERNATIONAL CORP US0123481089 0,27 USD 0,2486 EUR ALGOMA STEEL GROUP... ► Artikel lesen | |
HARMONY BIOSCIENCES | 35,250 | +1,00 % | Expert Outlook: Harmony Biosciences Holdings Through The Eyes Of 11 Analysts | ||
IMPACT BIOMEDICAL | 4,600 | +100,00 % | Impact Biomedical Inc. Announcement Stock Activity/Pricing | HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare... ► Artikel lesen | |
GALECTO | 5,890 | +34,78 % | Galecto, Inc.: Galecto Reports Full-Year 2024 Financial Results | Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen |